Company intelligence / Profile preview

Olaregen Therapeutix

New York City, New York, United Statesolaregen.com ↗

Ownership: Private
Development stage: Commercial

Overview

Olaregen’s lead product Excellagen® is FDA 510K cleared as a flowable dermal matrix for a broad array of dermal wounds. It is commercially available in the US with ongoing international expansion. Early clinical data support its efficacy in promoting healing across multiple wound types. The company is also developing pipeline products targeting bone/joint regeneration and rare diseases such as Ehlers-Danlos syndrome.

Therapeutic areas: EndocrinologyRare DiseasesDermatologyRheumatologyCardiovascularInfectious Diseases
Modalities: DeviceBiologicPlatform
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Excellagen

Commercial

Indications: Wound healing, Diabetic ulcers, Pressure ulcers, Venous ulcers

Partnerships

Nexgen Medical Sdn Bhd – exclusive distributor for Malaysia/Southeast Asia region

Beyond the preview

Go deeper on Olaregen Therapeutix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olaregen Therapeutix.